Related Experiment Video
Updated: Apr 28, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer
Jacinta Simasi1, Andreas Schubert2, Christopher Oelkrug2
1Fraunhofer Institut für Zelltherapie und Immunologie, Leipzig, Germany Institut für Pharmazie, Universität Leipzig, Germany jacinta.simasi@izi.fraunhofer.de.
Background:
Tyrosine kinase inhibitors (TKI) have emerged as important therapeutic agents for the treatment of several types of cancer including lung cancer. Recent research attempts show that only a small population of cancer patients responds to TKI and furthermore, these patients eventually develop resistance. Studies support the classification of resistance in primary and secondary resistance.
Materials And Methods:
In the present study the differentiation between primary and secondary resistance to TKI in lung cancer cell lines was investigated. Lung cancer cell lines were tested for viability, apoptosis and cell cycle after exposure to the TKI erlotinib and gefitinib.
Results:
Cells with primary resistance showed similar cell-cycle patterns to those with secondary resistance but differences were observed between the two groups in the viability and apoptosis assays.
Conclusion:
Understanding the effects of TKI on cell signaling pathways would shed light on the mechanisms of acquired resistance and the differences between primary and secondary resistance.
Insights
Tyrosine kinase inhibitors (TKI) show varied efficacy in lung cancer. This study differentiates primary and secondary TKI resistance, finding distinct viability and apoptosis patterns between resistant cell types.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKI) are crucial in cancer therapy, particularly for lung cancer.
- However, limited patient response and acquired resistance to TKIs present significant clinical challenges.
- Resistance is broadly classified into primary and secondary types.
Purpose of the Study:
- To investigate and differentiate between primary and secondary resistance to TKIs in lung cancer cell lines.
- To analyze the effects of specific TKIs on cellular processes in resistant cancer cells.
Main Methods:
- Utilized lung cancer cell lines to assess responses to erlotinib and gefitinib.
- Evaluated cell viability, apoptosis, and cell cycle progression after TKI exposure.
- Compared cellular behaviors between cells exhibiting primary and secondary resistance.
Main Results:
- Cells with primary resistance and secondary resistance displayed similar cell-cycle patterns.
- Significant differences were observed in viability and apoptosis assays between primary and secondary resistant cells.
- These findings highlight distinct cellular responses contributing to TKI resistance.
Conclusions:
- Understanding TKI effects on cell signaling is key to elucidating resistance mechanisms.
- Distinguishing between primary and secondary resistance can inform future therapeutic strategies.
- Further research into TKI-induced cell signaling pathways is warranted.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:56Treatment Resistent Cancers